In Vitro Cytotoxicity of Trastuzumab (Tz) and Se-Trastuzumab (Se-Tz) against the Her/2 Breast Cancer Cell Lines JIMT-1 and BT-474

Her/2+ breast cancer accounts for ~25% mortality in women and overexpression of Her/2 leads to cell growth and tumor progression. Trastuzumab (Tz) with Taxane is the preferred treatment for Her/2+ patients. However, Tz responsive patients often develop resistance to Tz treatment. Herein, redox selen...

Descripción completa

Detalles Bibliográficos
Autores principales: Bapat, Priyanka, Sewell, Debalina Goswami, Boylan, Mallory, Sharma, Arun K., Spallholz, Julian E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124313/
https://www.ncbi.nlm.nih.gov/pubmed/33925081
http://dx.doi.org/10.3390/ijms22094655

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124313/
https://www.ncbi.nlm.nih.gov/pubmed/33925081
http://dx.doi.org/10.3390/ijms22094655

Ejemplares similares